Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 17 June 2024
Accepted: 16 July 2024
First Online: 14 August 2024
Declarations
:
: Ricardo Correa-Rotter has received honoraria as consultant from AstraZeneca, Boehringer Ingelheim, Bayer, Chinook, AbbVie, Novo Nordisk, and research support from AstraZeneca, Boehringer Ingelheim, Roche and Novo Nordisk. He has received speaking fees from AstraZeneca, Boehringer Ingelheim, Novo Nordisk and Amgen. David C. Wheeler provides ongoing consultancy services to AstraZeneca in the last two years and has received honoraria and/or consultancy fees from Amgen, AstraZeneca, Boehringer Ingelheim, Bayer, Eledon, Galderma, Gilead, GlaxoSmithKline, George Clinical, Janssen, Merck Sharp and Dohme, ProKidney, Takeda, Vifor, and Zydus. He also reports speaking fees from Astellas, AstraZeneca and Vifor, and support for travel/meeting attendance from Astellas, AstraZeneca and Pro. He has served on DSMBs for Eledon, Galderma, Merck, and ProKidney. He is National Institute of Health Research Lead for Renal Disorders in the UK. Phil McEwan is an employee of Health Economics and Outcomes Research Ltd. Health Economics and Outcomes Research Ltd. received fees from AstraZeneca in relation to this study.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
